Corneal Neovascularization Clinical Trial
Official title:
Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.
The purpose of this study is to determine whether a novel subset of neutrophils is correlated with corneal neovascularization in the patients suffered from ocular chemical injury.
Cornea is an avascular transparent tissue providing refractive power for suitable optical performance. But under the condition of injury or infection, the stable microenvironment of ocular surface has been destroyed. Vessels sprout from the limbus to form corneal neovascularization, becoming an important pathological feature and leading cause of blindness. However, the underlying mechanism particular the inflammation-mediated mechanism remains unclear. With the advancement of single-cell RNA sequencing (scRNA-seq), the investigation of immune cell transcriptomes has obtained great process . Using this advanced method, we identified different immune cell types in the ocular surface microenvironment in corneal neovascularization mouse model. Particularly, we found a specific subset of neutrophils played important role during the corneal angiogenesis. Using the loss-of-function and gain-of-function experiment, we clarified that this novel subset of neutrophils is the major factor that promoting corneal angiogenesis in mouse model. To further explore the relationship between this subset of neutrophils and angiogenesis in human, we plan to detect whether the neutrophil subset is increased in the circulation of chemical burned corneal neovascularization patients. The main purpose of this study is to assess whether the novel subset of neutrophils has correlation with chemical burned corneal neovascularization. Approximately 33 patients and 33 age matched healthy controls will be recruited. The clinical characteristics, 4ml peripheral blood and the images of slit lamp photography will be obtained. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00555594 -
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
|
Phase 2/Phase 3 | |
Completed |
NCT00004430 -
Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization
|
N/A | |
Completed |
NCT00769145 -
Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
|
Phase 1 | |
Completed |
NCT01257750 -
Treatment of Corneal Neovascularization With Topical Pazopanib
|
Phase 1/Phase 2 | |
Recruiting |
NCT04787471 -
Corneal Crosslinking for Treatment of Corneal Neovascularization
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
Active, not recruiting |
NCT00992849 -
Bevacizumab for the Treatment of Corneal Neovascularization
|
Phase 2 | |
Withdrawn |
NCT00515684 -
Corneal Thinning During Topical Bevacizumab Therapy
|
N/A | |
Terminated |
NCT02797704 -
Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
Terminated |
NCT01868360 -
Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea
|
Phase 1 | |
Withdrawn |
NCT02042027 -
Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
|
Phase 1 | |
Recruiting |
NCT04215393 -
An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization
|
Phase 1 | |
Completed |
NCT00797303 -
The Effect of Bevacizumab on Corneal Neovascularization
|
Phase 4 | |
Completed |
NCT00559936 -
Topical Avastin for Treatment of Corneal Neovascularization
|
Phase 1 | |
Completed |
NCT01072357 -
Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
Recruiting |
NCT04620109 -
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
|
Phase 1 | |
Completed |
NCT00512876 -
Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization
|
N/A | |
Recruiting |
NCT05011916 -
The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 | |
Completed |
NCT01996826 -
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
|
Phase 1/Phase 2 | |
Terminated |
NCT00915590 -
Topical IL-1-Ra for Treatment of Corneal Neovascularization
|
Phase 1/Phase 2 |